Rapport Therapeutics, Inc.
RAPP Nasdaq
SEC CIK 2012593
Follow Rapport Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$40.2M
−49.4% vs same quarter last year
EPS, diluted
−$0.84
−18.3% vs same quarter last year
Operating cash flow
−$41.6M
−138.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$111.5M |
| FY24 | −$78.3M |
| FY23 | −$34.8M |
| FY22 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$88.1M |
| FY24 | −$67.2M |
| FY23 | −$28.8M |
| FY22 | - |